Medication Description: Solutizon (Soluthizonum)
Sodium methylene sulfonate para-aminobenzaltiosemikarbazona monohydrate.
Synonym: Tibon soluble.
Crystalline powder yellowish-green color. It is difficult and slowly soluble in water, practically insoluble in alcohol.
Solyutizon has, like thioacetazone (Tibon), bacteriostatic activity against Mycobacterium tuberculosis. The solubility in water allows the use of the drug for inhalation in the form of an aerosol, for lubrication or by intra-tornish and intrabronchial administration of the solution in the treatment of tuberculosis of the upper respiratory tract, bronchi and lungs. Solutisone is especially indicated in chronic fibro-cavernous tuberculosis, when anti-tuberculosis drugs do not penetrate well from the blood through the dense fibrous wall of the cavern. The solution can also be applied in the form of an aerosol or by intrabronchial administration for preparation in the surgical treatment of patients with chronic fibro-cavernous tuberculosis.
For inhalation appoint 2 to 3 ml of 1 - 2% solution (children 1% solution); session duration 7 - 10 - 12 min. The treatment is carried out for 1 to 2 months 1 to 2 times a day.
Depending on the indications, the course of treatment can be repeated.
Intratracheal inject 2 to 5 ml for the introduction of a 1 to 2% solution (using a laryngeal syringe).
Solutions are prepared immediately before use under aseptic conditions on distilled water. For better dissolution, heat to + 30 ° C, then cool to the desired temperature. Sterilization by heating is not carried out, since the drug decomposes at high temperatures.
Solutisone aerosol can be combined with the ingestion of other anti-tuberculosis drugs.
When using solutions of solythizone, irritation of the respiratory tract may occur, coughing; in these cases, treatment for several days interrupts or reduces the concentration of the solution (from 2% to 1%). In cases of intolerance, stop further inhalation of the solution of solutisone.
Inhalations of a solution of a solytizon are contraindicated in severe and decompensated forms of the fibro-cavernous process, cardiopulmonary insufficiency, candidiasis of the mucous membranes of the upper respiratory tract and the oral cavity.
Release form: powder; 2% solution in ampoules of 2 ml per pack of 10 ampoules.
Storage: List B. In the dark spot.